{"nct_id": "NCT06593522", "age": "Adults", "cancer_center_accrual_goal_upper": 0, "data_table4": "Interventional", "drug_list": {"drug": [{"drug_name": "Drug: AMG 193"}]}, "long_title": "A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)", "management_group_list": {"management_group": [{"is_primary": "Y", "management_group_name": "Group1"}]}, "oncology_group_list": {"oncology_group": [{"group_name": "Group1", "is_primary": "N"}]}, "phase": "PHASE2", "principal_investigator": "MD", "principal_investigator_institution": "Amgen", "program_area_list": {"program_area": [{"is_primary": "Y", "program_area_name": "Program1"}]}, "protocol_id": 0, "protocol_no": "", "protocol_target_accrual": 200, "protocol_type": "INTERVENTIONAL", "prior_treatment_requirements": ["Inclusion Criteria:", "* Histologically or cytologically confirmed metastatic or unresectable locally advanced MTAP-deleted (Homozygous deletion of MTAP in the tumor tissue) non-small cell lung cancer", "* Participants will have received and progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.", "* Either an archival tissue sample or an archival block must be available.", "* Life expectancy of greater than 3 months, in the opinion of the investigator.", "* Participants who have had brain metastases and have been appropriately treated with radiation therapy or surgery ending at least 14 days before study day 1 are eligible.", "* Participants with untreated asymptomatic brain metastases smaller or equal to 2 cm in size (per lesion if more than one) and not requiring corticosteroid treatment are eligible.", "Exclude - Exclusion Criteria:", "Exclude - Disease Related", "Exclude - \u2022 Tumors harboring the following mutations amenable to targeted therapies: epidermal growth factor receptor (EGFR), ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), MET proto-oncogene (MET), B-Raf proto-oncogene (BRAF), RET proto-oncogene (RET), Human epidermal growth factor receptor 2 (HER2), KRAS proto-oncogene (KRAS).", "Exclude - Other Medical Conditions", "Exclude - * Major surgery within 28 days of study day 1.", "Exclude - * Untreated symptomatic central nervous system (CNS) metastatic disease regardless of size or asymptomatic brain metastases greater than 2 cm per lesion."], "short_title": "A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC", "site_list": {"site": []}, "sponsor_list": {"sponsor": [{"is_principal_sponsor": "Y", "sponsor_name": "Amgen", "sponsor_protocol_no": "", "sponsor_roles": "sponsor"}]}, "staff_list": {"protocol_staff": []}, "status": "open to accrual", "summary": "The main objective of the study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).", "treatment_list": {"step": [{"arm": [{"arm_code": "Part 1: Dose Evaluation", "arm_internal_id": 0, "arm_description": "Participants will be randomized to receive one of 2 active dose levels of AMG 193 orally (PO) daily (QD) in 28 days cycles. Part 1 of the study will determine the recommended phase 2 dose (RP2D).", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: AMG 193", "level_internal_id": 0, "level_suspended": "N"}]}, {"arm_code": "Part 2: Dose Expansion", "arm_internal_id": 1, "arm_description": "Participants will receive AMG 193 PO QD in 28-day cycles at the RP2D.", "arm_suspended": "N", "dose_level": [{"level_code": "0", "level_description": "Drug: AMG 193", "level_internal_id": 0, "level_suspended": "N"}]}], "match": [{"and": [{"clinical": {"oncotree_primary_diagnosis": "", "disease_status": ["", ""]}}, {"genomic": {"hugo_symbol": "", "variant_category": ""}}]}]}]}}